Eli Lilly (LLY) and AbbVie (ABBV) are two prominent U.S. pharmaceutical companies with diverse and robust portfolios. Lilly has made significant strides in cardiometabolic health with its drugs Mounjaro and Zepbound, which are rapidly gaining market share in diabetes and obesity treatments, contributing to substantial revenue growth. AbbVie, on the other hand, has successfully transitioned from the loss of its blockbuster drug Humira by bolstering its immunology segment with Skyrizi and Rinvoq, which are projected to deliver strong sales growth in 2026.
Despite thriving in their respective areas, both companies face challenges. Lilly’s competitive landscape in GLP-1 therapies is intensifying, while AbbVie grapples with the impact of Humira’s biosimilars and pricing pressures. Financially, Lilly is seen as a more compelling growth investment due to its impressive growth trajectory and expanding product offerings, whereas AbbVie remains attractive for its stable pipeline and dividend yield. Ultimately, Lilly is favored for its stronger growth potential in the healthcare sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.tradingview.com/news/zacks:c1702eb41094b:0-lly-vs-abbv-which-stock-has-the-stronger-growth-prospects/
